Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2010

View Archived Issues

Albert Einstein College of Medicine claims hypoxia-targeted agents

Effect of citalopram on drinking depends on goals of alcohol-dependent subjects

RespiVert claims MAPK p38 inhibitors

AstraZeneca discovers new inhibitors of DAT and NET

Histamine H3 receptor ligands claimed by Merck & Co.

Merck & Co. claims new glucagon receptor antagonists

Nerviano describes new B-raf kinase inhibitors

BHT-3021 shows promise in phase I/II trial in type 1 diabetes

Weekly rituximab reduces proteinuria in idiopathic membranous nephropathy

Exelixis presents preclinical data on agents investigated for diabetes

Viamet describes new cytochrome P450-C17 inhibitors

Western States Biopharma and University of Colorado to develop TCISM-targeting agents

Selvita and Orion collaborate on SEL-103 program in AD

KAEL-GemVax reports phase III data on tertomotide in pancreatic cancer

Imiquimod superior to placebo in phase III program for external genital warts

Results reported from phase II study of gemcitabine/Amplimexon in pancreatic cancer

Midatech and Immunotope join to form Syntara to develop immune therapies

Adimab and Novartis partner after launch of antibody discovery platform

Interim phase IIb data reported on TMC-435 in HCV infection

FDA accepts Protalix's NDA for taliglucerase alfa

Hemispherx reports on Japanese trials of nasal H5N1 vaccine

JDRF awards Biodel grants for its VIAject diabetes therapy

Mesoblast and FDA to discuss phase III program for bone marrow regeneration

Quest PharmaTech forms clinical advisory panel for oregovomab

Clinuvel reports on phase III trial of Scenesse in EPP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...